이뮨온시아, IMC-001 상용화 전략 사실상 '후퇴'

Immunesia's retreat from direct commercialization to licensing-out reveals a fundamental constraint for Korean biotech: the $1.26 billion cost to develop IMC-001 for market far exceeds its projected domestic market of $60-300 million annually, making independent commercialization economically unsustainable. This reversal undermines the company's original positioning as Korea's first self-developed cancer immunotherapy to reach market and exposes why the industry remains structurally dependent on global pharma partnerships rather than building proprietary commercial capabilities.